What is the 13F Pro Quality Score for VTVT?

13F Pro ranks vTv Therapeutics Inc. (VTVT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTVT's current score at https://13fpro.ai/company/VTVT (free sign-up required for the full ranking).

Which hedge funds own the most VTVT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VTVT include Samsara BioCapital,, MILLENNIUM MANAGEMENT, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/VTVT as soon as new 13F filings post.

Where does 13F Pro source VTVT data?

All vTv Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. vTv Therapeutics Inc. files with the SEC under CIK 1641489. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTVT in?

vTv Therapeutics Inc. (VTVT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTVT research updated on 13F Pro?

VTVT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

vTv Therapeutics Inc.(VTVT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1641489 VTVT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $12.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

VTVT Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for vTv Therapeutics Inc. (VTVT), a Healthcare sector company. VTVT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $12.4m in revenue and is scored on the micro-cap board instead. Top institutional holders of VTVT by reported 13-F value include Samsara BioCapital, MILLENNIUM MANAGEMENT, FMR, based on the most recent SEC filings. VTVT trades on the Nasdaq exchange and files with the SEC under CIK 1641489. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for vTv Therapeutics Inc. directly from SEC EDGAR.

✦

Fun facts about vTv Therapeutics Inc.

Quirks, history, and lore behind VTVT — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in North Carolina · focused on small-molecule drug candidates.
2
The Numbers
A true micro-cap with minimal revenue — the company runs on research funding and partnerships rather than product sales, as is typical for a pre-commercial biotech.
3
The History
Spun out of TransEnterix predecessor lineage and rooted in research originally developed at GlaxoSmithKline, giving it a pipeline with deep Big Pharma DNA.
4
The Secret
Its lead focus has been Alzheimer's disease — one of the most punishing therapeutic areas in biotech, with a graveyard of failed trials that would make anyone nervous.
5
The Lore
The company has a licensing relationship with MacroGenics and has leaned on glucokinase activators and other metabolic-pathway approaches as part of its scientific identity.
6
The Giveaway
Its ticker is basically its name spelled out — a two-letter prefix followed by a Therapeutics suffix — and it has pursued an azeliragon program for Alzheimer's that kept investors watching for years.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-13.1M

ROIC

Q2 2026

-70.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $2.0MFY23 $0.00FY24 $1.0MFY25 $0.00

Net Income

-46.1% YoY

$-27.0MFY 2025

FY22 $-19.2MFY23 $-20.3MFY24 $-18.5MFY25 $-27.0M

Operating Income

-35.7% YoY

$-32.8MFY 2025

FY22 $-22.5MFY23 $-25.5MFY24 $-24.2MFY25 $-32.8M

Total Assets

+134.9% YoY

$89.9MFY 2025

FY22 $33.2MFY23 $11.0MFY24 $38.3MFY25 $89.9M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+0.2% YoY

$-25.3MFY 2025

FY22 $-16.0MFY23 $-19.1MFY24 $-25.3MFY25 $-25.3M

Free Cash Flow

—FY 2025

FY22 $-16.0MFY23 $-19.1MFY24 $-25.3MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$1.0M	$0.00 -100.0%	$2.0M -49.6%	$4.0M -37.6%	$6.4M
Net Income	$-27.0M -46.1%	$-18.5M +8.8%	$-20.3M -5.7%	$-19.2M -47.6%	$-13.0M -52.8%	$-8.5M
Operating Income	$-32.8M -35.7%	$-24.2M +5.2%	$-25.5M -13.1%	$-22.5M -4.1%	$-21.7M -82.8%	$-11.9M
Total Assets	$89.9M +134.9%	$38.3M +247.3%	$11.0M -66.9%	$33.2M +30.5%	$25.5M +72.2%	$14.8M
Total Debt	—	—	—	—	$256.0K +204.8%	$84.0K
Operating Cash Flow	$-25.3M +0.2%	$-25.3M -32.6%	$-19.1M -19.1%	$-16.0M +17.0%	$-19.3M -7.3%	$-18.0M
Free Cash Flow	—	$-25.3M -32.6%	$-19.1M -18.9%	$-16.0M +16.9%	$-19.3M -7.3%	$-18.0M

Get alerted when VTVT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for vTv Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTVT

Samsara BioCapital, LLC
$11.2M298,496 sh
MILLENNIUM MANAGEMENT LLC
$10.2M269,874 sh
FMR LLC
$9.8M260,391 sh
Siren, L.L.C.
$6.1M163,000 sh
BAKER BROS. ADVISORS LP
$5.6M148,314 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.6M94,463 sh
Trails Edge Capital Partners, LP
$3.2M85,192 sh
Aisling Capital Management LP
$1.9M50,000 sh
MARSHALL WACE, LLP
$1.5M39,560 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2M32,470 sh

Fund	Value	Shares
Samsara BioCapital, LLC	$11.2M	298,496
MILLENNIUM MANAGEMENT LLC	$10.2M	269,874
FMR LLC	$9.8M	260,391
Siren, L.L.C.	$6.1M	163,000
BAKER BROS. ADVISORS LP	$5.6M	148,314
VANGUARD CAPITAL MANAGEMENT LLC	$3.6M	94,463
Trails Edge Capital Partners, LP	$3.2M	85,192
Aisling Capital Management LP	$1.9M	50,000
MARSHALL WACE, LLP	$1.5M	39,560
GEODE CAPITAL MANAGEMENT, LLC	$1.2M	32,470

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTVT on your watchlist

Track score changes the day vTv Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTVT a good stock to buy?

13F Pro's AI-powered analysis of vTv Therapeutics Inc. (VTVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTVT are available on the VTVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VTVT is classified as a small company.

Which hedge funds own VTVT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of vTv Therapeutics Inc.'s investment landscape.